Tag: Health Care

Displaying 701 - 720 of 907 results.

Pages

Baxter settled Commission concerns stemming from its $316 million proposed acquisition of Wyeth Corporation's generic injectable drug business and agreed to divest several pharmaceutical products. The Commission charged that the acquisition would reduce competition in the manufacture...
Consent Order Will Preserve Competition in Markets for Certain General Anesthetics, Neuromuscular Blocking Agents, Antiemetics, and New Injectable Iron Replacement Therapies Under the terms of a proposed consent order designed to protect competition in several important pharmaceutical markets, the...
The Federal Trade Commission today released the materials relating to the workshop on Health Care Competition Law and Policy, held on September 9-10, 2002. The workshop focused on the implications of competition law and policy for health care financing and delivery and considered the impact of...
Chairman Timothy J. Muris in a speech today announced that the Federal Trade Commission will hold hearings on health care and competition law and policy commencing in February 2003 and continuing throughout the year. The hearings will be hosted jointly by the FTC and the Antitrust Division of the...
According to the staff of the Federal Trade Commission, a bill pending before the Ohio legislature that seeks to authorize competing physicians to engage in collective bargaining with health plans over fees and other contract terms likely would increase health care costs and reduce access to care...
Today, the Food and Drug Administration (FDA) proposed to clear away unnecessary roadblocks to the approval of generic drug products. I am encouraged by the FDA's important action to address the competitive problems existing in the approval process for generic drug products.
Following a public comment period, the Commission has approved the issuance of final consent orders and responses to the commenters of record in the matters concerning Philips Electronics and Okie Corporation. The Commission vote to approve the final consent orders was 5-0. (FTC File Nos. 022-3095...
Following a public comment period, the Commission has approved the issuance of a modified final consent order in the matter concerning Biovail Corporation (Biovail) and its branded drug Tiazac. Through the modification to the proposed order, Biovail's time to divest the relevant assets has been...
  Following a public comment period, the Commission has approved a final consent order, without modifications, and a letter to the commenter of record in the matter concerning Immunex Corporation and Amgen Inc. The vote to approve the final order and response to the commenter was 5-0. (FTC File No...
Joe Simons, Director of the Federal Trade Commission's Bureau of Competition, today announced the formation of the Merger Litigation Task Force, which will be headed by Michael Cowie, an Assistant Director in the Bureau of Competition. The Task Force will be responsible for reinvigorating the...
The Commission has approved the issuance of a final consent order in the matter concerning Biovail Corporation and Elan Corporation, plc, and authorized a response letter to be sent to the one commenter of record. The Commission vote to approve the final consent order and to issue the letter was 5...
Eight Denver, Colorado physician groups specializing in obstetrics and gynecology and their non-physician agent settled allegations that the practice group and other physicians entered into collective contracts in an effort to increase prices and terms of services when dealing with...
System Health Providers and its parent corporation, Genesis Physicians Group, Inc., settled charges that they collectively bargained with health insurance firms to accept proposed fee schedules; discouraged members from entering into contracts directly with payers; and refused to...
Under the terms of a proposed consent agreement announced today, the Federal Trade Commission would allow Amgen Inc.'s (Amgen) proposed $16 billion acquisition of Immunex Corporation (Immunex) to proceed, provided the companies divest certain assets and license certain intellectual property rights...
Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and...
In an initial decision filed on June 27, 2002 and announced today, Administrative Law Judge (ALJ) D. Michael Chappell dismissed all allegations of anticompetitive conduct in a March 2001 Federal Trade Commission complaint against pharmaceutical manufacturers Schering-Plough Corporation (Schering)...

Pages